By InvitationNot Applicable

A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

China100,000 participantsStarted 2026-02-13

Plain-language summary

The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participants had at least one prescription for Ozempic® or other interested anti-diabetic medications during the index identification period. * Participants had at least one diagnosis of T2D, and had at least one of the three following T2D clinical evidence any time before or on the index date * Participants had at least 1 all-cause visit record any time after 6 months post-index date. * At least 18 years old at the index date. Exclusion Criteria: * Patients who have used any same anti-diabetic medications as the index treatment within 6 months before index date (e.g., patient prescribed with any Ozempic® during baseline will be excluded if the index drug is a Ozempic®) * Patients with any diagnosis record of type 1 diabetes or gestational diabetes during whole study period. * Patients who were pregnant during the whole study period. * Patients who participated in any clinical trials during the whole study period. * Patients who were diagnosed with medullary thyroid carcinoma or multiple endocrine neoplasia type II (MEN2) during the whole study period.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This study is tracking serious outcomes like heart attacks, strokes, heart failure, and kidney disease — does my current health situation put me at meaningful risk for any of these, and would being in a real-world observational study like this actually change the treatment I receive?
2Since this trial is described as 'enrolling by invitation,' can you find out whether I might be eligible to be invited, and who is making those invitation decisions in China?
3This study compares once-weekly semaglutide (Ozempic) against other diabetes medications for adherence and long-term cardiovascular and kidney outcomes — based on my specific situation, do you think semaglutide is already the right choice for me, or would standard treatment options be a better starting point?
4Because this is labeled as a real-world study rather than a traditional randomized controlled trial, what does that mean for how the results will be interpreted, and does it affect what I can expect in terms of personalized monitoring or follow-up?
5The trial is measuring time to events like stroke and kidney disease hospitalization, which suggests this is a longer-term study — what kind of follow-up commitment would this involve, and how would participation fit alongside my regular diabetes care?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Time to 3P major adverse cardiovascular events

Timeframe: From index date to the first composite 3P MACE (stroke, myocardial infarction, all-cause death) event or censoring event (up to 36 months)

Time to 5P MACE

Timeframe: From index date to the first composite 5P MACE (stroke, myocardial infarction, all-cause death, heart failure hospitalization, coronary revascularization) event or censoring event (up to 36 months)

Time to stroke

Timeframe: From index date to the first stroke event or censoring event (up to 36 months)

Time to myocardial infarction (MI)

Timeframe: From index date to the first MI event or censoring event (up to 36 months)

Time to heart failure (HF)

Timeframe: From index date to the first HF event or censoring event (up to 36 months)

Time to composite renal event

Timeframe: From index date to first composite renal (kidney failure: dialysis/transplantation/eGFR <15, ≥50% eGFR reduction from baseline, or kidney-related/cardiovascular death) or censoring event (up to 36 months)

Trial details

NCT IDNCT07456774

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-08-31

View on ClinicalTrials.gov More Type 2 Diabetes trials